Bavarian Nordic doses first patient in Phase II trial of CV-301 to treat bladder cancer
Denmark-based biotechnology firm Bavarian Nordic has dosed first patient in a randomised, prospective Phase II trial of its active immunotherapy ...
Denmark-based biotechnology firm Bavarian Nordic has dosed first patient in a randomised, prospective Phase II trial of its active immunotherapy ...
Janssen-Cilag International (Janssen) has received approval from the European Commission (EC) for use of Vokanamet in the European Union (EU) ...
The National Institute for Health and Care Excellence (NICE) in the UK has issued its final health technology appraisal recommending ...
Copenhagen, Denmark, February 21, 2014 - Today announced that it has entered an exclusive license agreement with a subsidiary of ...
A Phase IIa clinical study will test the efficacy, safety and tolerability profile Ferrer, a privately-held Spanish pharmaceutical company, today announces ...
Roche announced the launch of the SeqCap Epi Target Enrichment System for DNA methylation assessment at single-base resolution. This system ...
PharmaCell B.V. a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, announced today that it has ...
A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a ...
Reservoirs of pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for slow, concentrated delivery ...
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.